Boston Scientific (BSX) Stock Overview
Develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BSX from our risk checks.
BSX Community Fair Values
Create NarrativeSee what 129 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$98.9
FV
42.8% undervalued intrinsic discount9.80%
Revenue growth p.a.
274
users have viewed this narrative1users have liked this narrative
1users have commented on this narrative
14users have followed this narrative
Boston Scientific Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$56.57 |
| 52 Week High | US$109.50 |
| 52 Week Low | US$54.98 |
| Beta | 0.62 |
| 1 Month Change | -8.55% |
| 3 Month Change | -25.83% |
| 1 Year Change | -45.23% |
| 3 Year Change | 5.96% |
| 5 Year Change | 35.95% |
| Change since IPO | 1,221.34% |
Recent News & Updates
Narrative Update • May 08
BSX: Clinical Wins And Pipeline Strength Will Support Rebased Expectations
Analysts have trimmed the Boston Scientific fair value estimate from $95.75 to $85.19 after a series of price target cuts across the Street. The change reflects updated assumptions for slower revenue growth, slightly higher profit margins, and a lower forward P/E multiple.
New Narrative • Apr 24
Minimally Invasive Therapies And Atrial Fibrillation Treatments Will Support Steady Prospects Ahead
Catalysts About Boston Scientific Boston Scientific is a global medical technology company that develops and sells devices used in cardiology, electrophysiology, urology, endoscopy, neuromodulation and other interventional procedures. What are the underlying business or industry changes driving this perspective?Recent updates
Narrative Update • May 08
BSX: Clinical Wins And Pipeline Strength Will Support Rebased Expectations
Analysts have trimmed the Boston Scientific fair value estimate from $95.75 to $85.19 after a series of price target cuts across the Street. The change reflects updated assumptions for slower revenue growth, slightly higher profit margins, and a lower forward P/E multiple.New Narrative • Apr 24
Minimally Invasive Therapies And Atrial Fibrillation Treatments Will Support Steady Prospects Ahead
Catalysts About Boston Scientific Boston Scientific is a global medical technology company that develops and sells devices used in cardiology, electrophysiology, urology, endoscopy, neuromodulation and other interventional procedures. What are the underlying business or industry changes driving this perspective?Narrative Update • Apr 22
BSX: Clinical Trial Wins Will Offset Reset Expectations And Battery Concerns
Analysts have trimmed the fair value estimate for Boston Scientific to $95.75 from $100.31, reflecting a series of lower Street price targets and slightly more conservative assumptions on growth, profitability, and future P/E multiples. Analyst Commentary Recent research coverage on Boston Scientific has centered on a broad reset of expectations, with many firms revising price targets and, in some cases, ratings.
New Narrative • Apr 08
Pulsed Field Ablation And Minimally Invasive Therapies Will Reshape Long Term Procedure Volumes
Catalysts About Boston Scientific Boston Scientific develops and sells medical devices across cardiovascular, electrophysiology, neuromodulation, endoscopy, urology and related therapeutic areas worldwide. What are the underlying business or industry changes driving this perspective?Narrative Update • Apr 07
BSX: Clinical Wins And 2026 Outlook Will Outweigh Pacemaker Battery Concerns
Boston Scientific's analyst fair value estimate shifts modestly lower from $102.00 to about $100.31, as analysts recalibrate price targets across the group following recent clinical data, rating changes, and updated sector models. Analyst Commentary Recent Street research around Boston Scientific clusters around a common theme, with many firms trimming price targets and a smaller group highlighting potential upside tied to execution and clinical progress.Seeking Alpha • Mar 25
Boston Scientific: Under Pressure, But Could See A Shift In Fortunes (Rating Upgrade)
Summary Boston Scientific has contracted by over 30% over the past year, grossly underperforming other medical equipment stocks and healthcare stocks from the S&P 500. Yet, amidst the ongoing pressure, we are now upgrading the stock from hold to buy, as we believe growth will pick up from H2 and expand even further next year. Besides, BSX no longer looks expensive from an earnings perspective and is priced at a compelling forward multiple of 20x while also offering an impressive forward FCF yield of 4%. BSX no longer looks like one of the more overbought stocks in the healthcare cohort of the S&P 500, while the selling pressure on BSX's long-term charts looks to have gone overboard. Read the full article on Seeking AlphaNarrative Update • Mar 24
BSX: Reorganized Segments And 2026 Outlook Should Offset Recent Pacemaker Headlines
Analysts have trimmed the Boston Scientific fair value estimate by about $2 to $102, reflecting a series of reduced Street price targets that incorporate slightly lower revenue growth assumptions, a marginally higher discount rate, and modest tweaks to long term margin and future P/E expectations. Analyst Commentary Street research on Boston Scientific has been active, with most recent moves clustered around price target resets and list changes.Narrative Update • Mar 08
BSX: Reorganized Segments And 2026 Outlook Should Support Sentiment Rebound
Analysts have trimmed their blended price target on Boston Scientific by about $0.50 to roughly $104.25. This reflects updated models following the company reorganization and recent management commentary.Narrative Update • Feb 22
BSX: Organizational Changes Should Support Rebound As 2026 Patterns Normalize
Analysts have trimmed their average price target on Boston Scientific to $104.75 from $108.66, citing updated models that factor in recent organizational changes and management commentary following the latest earnings call. Analyst Commentary Across Wall Street, most research updates on Boston Scientific center on revised models and valuation resets rather than outright changes in long term views.Narrative Update • Feb 06
BSX: Execution Outperformance Should Drive Rebound As 2026 Patterns Normalize
The analyst price target for Boston Scientific has been reduced by about $17 to align with updated Street research. This reflects slightly lower revenue growth assumptions, a modestly higher discount rate, and a lower future P/E multiple, while profit margin expectations remain steady.
New Narrative • Jan 25
BSX after Penumbra ?
The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons: * Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this "EPS drag" by pulling back, which we've seen in the recent price dips.Narrative Update • Jan 10
BSX: Shares Should Rise On Execution Outperformance And 2026 Normalization Potential
Analysts have trimmed their Boston Scientific fair value estimate slightly to about $125.45 from $125.86, reflecting fine tuning of discount rate, revenue growth, profit margin and future P/E assumptions in light of recent price target resets and largely supportive research commentary across the MedTech sector. Analyst Commentary Recent Street research on Boston Scientific reflects generally constructive views on execution and growth, with some recalibration of targets as models are updated after quarterly results and sector wide resets.Narrative Update • Dec 25
BSX: Shares Will Rise On Execution Outperformance And Three Year Growth Plan
Analysts have nudged their fair value estimate for Boston Scientific slightly lower to approximately $126 per share, even as multiple firms have lifted price targets into the $124 to $136 range, citing sustained double digit revenue growth, a robust pipeline, and potential upside from recent acquisitions and Q3 outperformance. Analyst Commentary Bullish analysts largely frame Boston Scientific as a durable double digit grower with room for further multiple expansion, pointing to recent Q3 upside, raised long term targets, and a steady cadence of accretive deals as support for valuations near or above current levels.Narrative Update • Dec 11
BSX: Shares Will Rise On Earnings Strength And Multi Year Execution Momentum
Analysts nudged their average price target for Boston Scientific modestly higher, toward the low to mid $130 range, citing the company’s Q3 beat, accelerating Watchman adoption, confidence in multi year guidance, and a robust growth pipeline supported by strategic acquisitions like Nalu, despite some cautions on valuation and longer term growth moderation. Analyst Commentary Analyst reaction to Boston Scientific's latest results and strategic updates has been predominantly positive, with several firms raising price targets and reiterating favorable ratings, while a minority voice has started to flag valuation and medium term growth risks.Narrative Update • Nov 27
BSX: Shares Will Advance On Earnings Strength And Merger Execution Momentum
Boston Scientific's analyst price targets have been raised by several dollars, with most now clustered around $130 per share. Analysts highlight robust quarterly results, accelerating growth segments, and confidence in the company’s long-range outlook.Narrative Update • Nov 07
BSX: Shares Will See Momentum From Recent Acquisition And Execution Confidence
Boston Scientific's analyst price target has been increased modestly, with the consensus now reflecting a higher fair value in addition to ongoing confidence in robust growth prospects and recent business performance, as analysts cite solid quarterly results, improving guidance, and successful strategic acquisitions. Analyst Commentary Recent analyst research on Boston Scientific highlights both optimistic and cautious perspectives regarding the company's valuation, strategic moves, and long-term growth outlook.Narrative Update • Oct 24
Future Growth Plans And Acquisitions Will Drive Broader Market Expansion
Analysts have raised their price target for Boston Scientific to approximately $126, up from $124.53. They cite renewed confidence in the company’s earnings outlook, along with improvements in profit margin and future growth expectations, following strong quarterly performance.Analysis Article • Jul 21
Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analysis Article • Jul 04
Returns At Boston Scientific (NYSE:BSX) Are On The Way Up
If you're looking for a multi-bagger, there's a few things to keep an eye out for. One common approach is to try and...Seeking Alpha • Mar 18
Boston Scientific: Bright Future, Rather Pricey
Summary A diversified portfolio, strategic acquisitions, and aggressive R&D have driven Boston Scientific's recent revenue and EPS growth, outpacing peers like Abbott and Medtronic. Consequently, BSX stock is trading at a significant premium, reflecting high investor optimism. Intense competition along with regulatory and safety concerns also remain key challenges. While Boston's fundamentals suggest that double-digit earnings growth can be sustained, there may be little margin for error at the current stock price. I recommend a Hold at ~$97. Read the full article on Seeking AlphaSeeking Alpha • Jan 14
Boston Scientific Standing Apart As A Rare Med-Tech Growth Story
Summary BSX shares have continued to outpace competitors like Abbott, Johnson & Johnson, and Medtronic, driven by strong performance across multiple business lines. Innovative atrial fibrillation devices like Farapulse and Watchman are achieving 20%+ annual growth, while coronary care, peripheral, and urology continue to grow at/near double-digit rates. Recent purchases of Silk Road and Bolt Medical position BSX to expand in complementary carotid artery and intravascular lithotripsy markets. Risks include margin pressures, clinical setbacks, and sky-high growth expectations, with valuation leaving no room for missteps. A mid-teens revenue growth rate can support further double-digit gains, but valuation reflects a lot of BSX's exceptional traits. Read the full article on Seeking AlphaShareholder Returns
| BSX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -1.8% | -3.4% | 2.1% |
| 1Y | -45.2% | -21.0% | 30.6% |
Return vs Industry: BSX underperformed the US Medical Equipment industry which returned -21% over the past year.
Return vs Market: BSX underperformed the US Market which returned 30.6% over the past year.
Price Volatility
| BSX volatility | |
|---|---|
| BSX Average Weekly Movement | 5.4% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BSX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BSX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 59,000 | Mike Mahoney | www.bostonscientific.com |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems.
Boston Scientific Corporation Fundamentals Summary
| BSX fundamental statistics | |
|---|---|
| Market cap | US$83.24b |
| Earnings (TTM) | US$3.57b |
| Revenue (TTM) | US$20.61b |
23.6x
P/E Ratio4.1x
P/S RatioIs BSX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BSX income statement (TTM) | |
|---|---|
| Revenue | US$20.61b |
| Cost of Revenue | US$6.40b |
| Gross Profit | US$14.21b |
| Other Expenses | US$10.65b |
| Earnings | US$3.57b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 29, 2026
| Earnings per share (EPS) | 2.40 |
| Gross Margin | 68.94% |
| Net Profit Margin | 17.29% |
| Debt/Equity Ratio | 41.8% |
How did BSX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/07 15:37 |
| End of Day Share Price | 2026/05/07 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Boston Scientific Corporation is covered by 63 analysts. 30 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| David Rescott | Baird |
| null null | Baird |